Cannabidiol + delta 9 tetrahydrocannabinol

Unassigned

New Medicines

Caumz · Cancer cachexia in patients with advanced incurable cancer

Information

Caumz
New formulation
Tetra Bio-Pharma
Tetra Bio-Pharma

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Cannabinoid receptor agonist presented in a CAUMZ™ Kit which comprises of capsules coated with 17mg delta-9-tetrahydrocannibinol and 5mg cannabidiol with a handheld Mighty Medic vaporiser
Cancer cachexia is present in approximately 50% of cancer patients during treatment, and nearly 100% of treated cancer patients at death. It accounts for at least 20% of deaths in neoplastic patients. Cancer cachexia impairs quality of life and response to therapy, increasing morbidity and mortality of cancer patients [10].
Cancer cachexia in patients with advanced incurable cancer
Inhalation